These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22623162)

  • 1. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
    Salaroli A; Loglisci G; Serrao A; Alimena G; Breccia M
    Ann Hematol; 2012 Nov; 91(11):1823-4. PubMed ID: 22623162
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 3. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
    Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
    Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
    [No Abstract]   [Full Text] [Related]  

  • 4. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
    Cornfield D; Shah U; Cross N; Bennett C; Sun G
    J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
    [No Abstract]   [Full Text] [Related]  

  • 5. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps.
    Pickup JC
    Diabetes Technol Ther; 2011 Jul; 13(7):695-8. PubMed ID: 21668344
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
    Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
    Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypoglycemia in diabetic children].
    Tupola S; Rajantie J
    Duodecim; 2000; 116(2):125-31. PubMed ID: 11764469
    [No Abstract]   [Full Text] [Related]  

  • 9. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
    Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
    Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
    Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
    Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
    Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
    Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
    [No Abstract]   [Full Text] [Related]  

  • 14. Lichenoid eruption due to imatinib.
    Prabhash K; Doval DC
    Indian J Dermatol Venereol Leprol; 2005; 71(4):287-8. PubMed ID: 16394444
    [No Abstract]   [Full Text] [Related]  

  • 15. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
    Bally L; Thabit H; Hovorka R
    Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.
    Tipirneni E; Buttar A; Brettler D; Miron P; Bathini V
    Ann Hematol; 2012 Apr; 91(4):637-8. PubMed ID: 21833478
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of Predictive Low-Glucose Management System in Hybrid of Full Closed Loop System.
    Choudhary P
    Diabetes Technol Ther; 2016 Jul; 18(7):408-9. PubMed ID: 27379979
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.